A Brief History of REGEN-COV: A Monoclonal Antibody Cocktail by Regeneron for the Treatment of COVID-19

Time – Sat, 05/22, 12:00 – 1:30PM PDT

Where: https://lnkd.in/dmbGP66 (Click the link to register)

             Free for EPPIC Global Members

              $20 for Non-members

Antibodies targeting the spike protein of SARS-CoV-2 have proven to be effective both as treatment and prophylaxis in a clinical setting. REGEN-COV is a combination of two potently neutralizing non-competing antibodies selected through parallel efforts using both humanized mice and convalescent patients from thousands of monoclonal antibody candidates. Due to the non-competing properties of the two antibodies, the REGEN-COV combination provides protection against development of drug resistant variants in vitro, in vivo, and in the clinical setting. Furthermore, REGEN-COV retains potency against all current variants of concern or interest, including the B.1.351 (South Africa), P.1 (Brazil), and B.1.427 (CA) variants. Regeneron scientists will discuss some of the non-clinical and clinical experimental data that have been generated in the development of REGEN-COV.

Would you like to hear directly from the developers of the REGEN-COV monoclonal antibody created by Regeneron Pharmaceuticals? With the ongoing struggle of the COVID pandemic, come hear about the background of REGEN-COV on 22nd May from 12:00-1:30PM PDT. Speakers Dr. Alina Baum, PhD, Associate Director of Infectious Diseases at Regeneron, Dr. John Davis, Head of Clinical Pharmacology at Regeneron and Dr.Johanna Hansen, PhD, Director, Cell Technologies, Protein Expression Sciences at Regeneron Pharmaceuticals will all be presenting along with a Q&A session moderated by Dr. Sandhya Mandlekar from Genentech!

Event Information

Event Topic:
A Brief History of REGEN-COV: A Monoclonal Antibody Cocktail by Regeneron for the Treatment of COVID-19

Event Description:

Date/Time:
Date(s) - 05/22/21
12:00 pm - 1:30 pm

Event Location:
Other:

Event Details

Event Type